YARROW BIOSCIENCE, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
YARROW BIOSCIENCE, INC. (YARW) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 5.87 million shares for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-03.
Discontinued › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2020-03-03
- YARROW BIOSCIENCE, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2019-03-31 was 6.18M shares, a 2.75% decline year-over-year.
- YARROW BIOSCIENCE, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2018-03-31 was 6.36M shares, a 22.07% decline year-over-year.
- YARROW BIOSCIENCE, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2017-03-31 was 8.16M shares.
- YARROW BIOSCIENCE, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2019 was 5.87M shares, a 45.82% increase from fiscal 2018.
- YARROW BIOSCIENCE, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2018 was 4.02M shares, a 67.21% decline from fiscal 2017.
- YARROW BIOSCIENCE, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2017 was 12.28M shares, a 76.84% increase from fiscal 2016.
- YARROW BIOSCIENCE, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2016 was 6.94M shares, a 4.16% decline from fiscal 2015.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|
| 2019-12-31 | 5.87M shares 10-K · filed 2020-03-03 | |||||
| 2019-09-30 | 6.55M shares 10-Q · filed 2019-10-31 | |||||
| 2019-06-30 | 6.60M shares 10-Q · filed 2019-08-01 | |||||
| 2019-03-31 | 6.18M shares 10-Q · filed 2019-05-02 | |||||
| 2018-12-31 | 4.02M shares 10-K · filed 2020-03-03 | |||||
| 2018-09-30 | 5.39M shares 10-Q · filed 2019-10-31 | 3.19M shares 10-Q · filed 2018-11-07 | ||||
| 2018-06-30 | 5.60M shares 10-Q · filed 2019-08-01 | |||||
| 2018-03-31 | 6.36M shares 10-Q · filed 2019-05-02 | |||||
| 2017-12-31 | 12.28M shares 10-K · filed 2020-03-03 | 12.69M shares 10-K · filed 2018-03-28 | ||||
| 2017-09-30 | 11.94M shares 10-Q · filed 2018-11-07 | |||||
| 2017-06-30 | 7.83M shares 10-Q · filed 2018-08-01 | |||||
| 2017-03-31 | 8.16M shares 10-Q · filed 2018-05-09 | |||||
| 2016-12-31 | 6.94M shares 10-K · filed 2019-02-28 | 7.14M shares 10-K · filed 2018-03-28 | ||||
| 2015-12-31 | 7.24M shares 10-K · filed 2018-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |